2269 N Stock Overview An investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. More details
Rewards Risk Analysis See All Risk Checks {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Capture your thoughts, links and company narrative
WuXi Biologics (Cayman) Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for WuXi Biologics (Cayman) Historical stock prices Current Share Price HK$62.53 52 Week High HK$62.53 52 Week Low HK$62.53 Beta 0.66 1 Month Change 0% 3 Month Change n/a 1 Year Change n/a 3 Year Change -74.45% 5 Year Change n/a Change since IPO -73.63%
Recent News & Updates
WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718). Oct 25
WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom Oct 05
WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing Aug 30
WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024 Jul 25
Wuxi Biologics (Cayman) Inc. Announces Retirement of Weichang Zhou as Chief Technology Officer and President of Global Biologics Development and Operations and Re-Designates as Non-Executive Director and Honorary President of Global Biologics Development and Operations and Senior Advisor to Chief Executive Officer Apr 03
WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024 Mar 27 See more updates
WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718). Oct 25
WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom Oct 05
WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing Aug 30
WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024 Jul 25
Wuxi Biologics (Cayman) Inc. Announces Retirement of Weichang Zhou as Chief Technology Officer and President of Global Biologics Development and Operations and Re-Designates as Non-Executive Director and Honorary President of Global Biologics Development and Operations and Senior Advisor to Chief Executive Officer Apr 03
WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024 Mar 27
WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P Global 1200 Mar 19 WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700
WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024 Feb 15
WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland Feb 01
WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect Jan 25
WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™ Jan 17
WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024 Jan 16
Less than half of directors are independent Dec 22
WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023. Dec 08
Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale Nov 22
WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality Oct 17
Wuxi Biologics (Cayman) Inc. Announces Executive Changes Aug 17
WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023 Jul 26 WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023 May 25
WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee May 18
WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes May 09
Investor sentiment deteriorates as stock falls 26% Feb 23
Less than half of directors are independent Feb 23 WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023
Less than half of directors are independent Jan 31
WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company Nov 26
Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee Nov 24
WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022. Oct 01
First half 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.44 in 1H 2021) Sep 24
WuXi Biologics (Cayman) Inc. Receives Regulatory Approvals for Drug Substance and Drug Product Facilities from U.S. FDA and EMA Sep 20
Investor sentiment deteriorated over the past week Sep 19
Less than half of directors are independent Sep 19
First half 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.44 in 1H 2021) Aug 18
Less than half of directors are independent Aug 18
WuXi Biologics (Cayman) Inc. Appoints Weichang Zhou as Member of the Strategy Committee Aug 18 WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022
Less than half of directors are independent Jul 18
CEO & Executive Director recently sold Mex$45m worth of stock Jun 17
Investor sentiment improved over the past week Jun 13
Less than half of directors are independent May 30
Less than half of directors are independent Feb 12 Wuxi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Ended December 31, 2021
WuXi Biologics Announces Completion of GMP Production At 24,000L Line of Its Drug Substance Facility MFG5 Nov 24
CEO & Executive Director recently bought Mex$102m worth of stock Nov 07
Less than half of directors are independent Oct 26
WuXi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021 Jul 15
CEO & Executive Director recently sold Mex$88m worth of stock Jun 17 WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd.
Full year 2020 earnings released: EPS CN¥0.43 (vs CN¥0.27 in FY 2019) May 01
Insider recently bought Mex$9.2m worth of stock Mar 31
Full year 2020 earnings released: EPS CN¥0.43 (vs CN¥0.27 in FY 2019) Mar 25
WuXi Biologics (Cayman) Inc. (SEHK:2269) agreed to acquire a 90% stake in CMAB Biopharma Inc. from CBC Group. Mar 19
WuXi Biologics (Cayman) Inc. (SEHK:2269) entered into an equity agreement to acquire Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd. Mar 17
Exelixis, Inc. Enters into License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline Mar 10
Wuxi Biologics (Cayman) Inc. Receives Remote Pre-Approval Inspection by European Medicines Agency on MFG4 Facility Mar 04
WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2020 Results on Mar 23, 2021 Feb 27
Antengene Corporation Limited Announces Collaboration with WuXi Biologics and WuXi STA to Advance Antibody-Drug Conjugate Candidate into Clinical-stage Feb 01
Executive VP recently sold Mex$275m worth of stock Jan 28
Oxford BioTherapeutics Ltd Designates Second Bispecific Antibody Program Leveraging Wuxi Biologics’ Wuxibody® Platform Jan 21
Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform Jan 20
WuXi Biologics Receives GMP Certification from Brazil's ANVISA Dec 29 Shareholder Returns 2269 N MX Life Sciences MX Market 7D 0% 0% 0% 1Y n/a 0% 0%
See full shareholder returns
Return vs Market: Insufficient data to determine how 2269 N performed against the MX Market .
Price Volatility Is 2269 N's price volatile compared to industry and market? 2269 N volatility 2269 N Average Weekly Movement n/a Life Sciences Industry Average Movement 0% Market Average Movement 0% 10% most volatile stocks in MX Market 0% 10% least volatile stocks in MX Market 0%
Stable Share Price: 2269 N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 2269 N's volatility change over the past year.
About the Company WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development, and manufacturing in the People’s Republic of China, North America, Europe, and internationally. It also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and material supplier activities. The company has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates.
Show more WuXi Biologics (Cayman) Inc. Fundamentals Summary How do WuXi Biologics (Cayman)'s earnings and revenue compare to its market cap? 2269 N fundamental statistics Market cap Mex$132.67b Earnings (TTM ) Mex$9.71b Revenue (TTM ) Mex$38.71b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2269 N income statement (TTM ) Revenue CN¥16.55b Cost of Revenue CN¥9.68b Gross Profit CN¥6.87b Other Expenses CN¥2.72b Earnings CN¥4.15b
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Mar 26, 2024
Earnings per share (EPS) 0.99 Gross Margin 41.51% Net Profit Margin 25.08% Debt/Equity Ratio 7.7%
How did 2269 N perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/03/18 08:24 End of Day Share Price 2023/12/20 00:00 Earnings 2023/06/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources WuXi Biologics (Cayman) Inc. is covered by 56 analysts. 32 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Wai Chak Yuen BOCI Research Ltd. Linda Lu BOCI Research Ltd. Bo Li BofA Global Research
Show 53 more analysts 